Sulfuric Acid

Sulfuric Acid

SCHEMBL1101232

C=CCn1cc[n+](C)c1.O=S(=O)([O-])O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CYP51cyp51Acyp51c

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 1/20 0.36
APAF1 O14727 1/20 0.36
NPC1 O15118 1/20 0.36
PLA2G1B P04054 1/20 0.36
HSP90AA1 P07900 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL30712585 0.93 FDPS (0.39) FDPSSMN1; SMN2MEN1APAF1NPC1
Sulfuric Acid SCHEMBL28517102 0.93 FDPS (0.39) FDPSSMN1; SMN2MEN1APAF1NPC1
SCHEMBL4281206 0.92 FDPS (0.38) FDPSSMN1; SMN2MEN1APAF1NPC1
SCHEMBL14635383 0.88 FDPS (0.35) FDPSSMN1; SMN2MEN1APAF1NPC1
SCHEMBL9934092 0.88 FDPS (0.38) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL16668993 0.87 FDPS (0.36) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL4920095 0.86 FDPS (0.37) FDPSSMN1; SMN2MEN1APAF1NPC1
SCHEMBL205339 0.86
Acetic Acid SCHEMBL2031476 0.85 FDPS (0.41) FDPSSMN1; SMN2MEN1APAF1NPC1
Formic Acid SCHEMBL17076871 0.85 FDPS (0.40) FDPSSMN1; SMN2MEN1APAF1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111834641-B Preparation method of carbon felt modified by graphene in ionic liquid 中国科学院过程工程研究所 2022-03-15 CN claimed
US-8148518-B2 Cellulose esterification; ion exchanging; acylation; slurrying EASTMAN CHEMICAL COMPANY (US) 2012-04-03 US claimed
EP-2121766-A1 CELLULOSE ESTERS AND THEIR PRODUCTION IN CARBOXYLATED IONIC LIQUIDS Eastman Chemical Company (US) 2009-11-25 EP claimed
WO-2008100566-A1 CELLULOSE ESTERS AND THEIR PRODUCTION IN CARBOXYLATED IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2008-08-21 WO claimed
US-20080194808-A1 CELLULOSE ESTERS AND THEIR PRODUCTION IN CARBOXYLATED IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2008-08-14 US claimed
EP-3239179-B1 REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS PRODUCED IN A CARBOXYLATED IONIC LIQUID PROCESS AND PRODUCTS PRODUCED THEREFROM EASTMAN CHEM CO (US) 2023-02-22 EP disclosed
CN-111834641-B Preparation method of carbon felt modified by graphene in ionic liquid 中国科学院过程工程研究所 2022-03-15 CN disclosed
CN-103923352-B Regioselectively substituted cellulose esters prepared by carboxylated ionic liquid processes and products prepared therefrom 伊士曼化工公司 2020-10-16 CN disclosed
EP-2313438-B1 REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS PRODUCED IN A HALOGENATED IONIC LIQUID PROCESS AND PRODUCTS PRODUCED THEREFROM EASTMAN CHEM CO (US) 2019-09-18 EP disclosed
US-10174129-B2 Regioselectively substituted cellulose esters produced in a carboxylated ionic liquid process and products produced therefrom EASTMAN CHEMICAL COMPANY (US) 2019-01-08 US disclosed
US-9834516-B2 Regioselectively substituted cellulose esters produced in a carboxylated ionic liquid process and products produced therefrom EASTMAN CHEMICAL COMPANY (US) 2017-12-05 US disclosed
EP-3239179-A1 REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS PRODUCED IN A CARBOXYLATED IONIC LIQUID PROCESS AND PRODUCTS PRODUCED THEREFROM Eastman Chemical Company (US) 2017-11-01 EP disclosed
US-20090203900-A1 PRODUCTION OF CELLULOSE ESTERS IN THE PRESENCE OF A COSOLVENT EASTMAN CHEMICAL COMAPANY (US) 2009-08-13 US disclosed
US-20090203898-A1 CELLULOSE ESTERS AND THEIR PRODUCTION IN HALOGENATED IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2009-08-13 US disclosed
WO-2008100566-A1 CELLULOSE ESTERS AND THEIR PRODUCTION IN CARBOXYLATED IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2008-08-21 WO disclosed
WO-2008100569-A1 REFORMATION OF IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2008-08-21 WO disclosed
WO-2008100577-A1 PRODUCTION OF IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2008-08-21 WO disclosed
US-20080194834-A1 PRODUCTION OF IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2008-08-14 US disclosed
US-20080194808-A1 CELLULOSE ESTERS AND THEIR PRODUCTION IN CARBOXYLATED IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2008-08-14 US disclosed
US-20080194807-A1 REFORMATION OF IONIC LIQUIDS EASTMAN CHEMICAL COMPANY (US) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194834-A1 PRODUCTION OF IONIC LIQUIDS GLUL, ICMT, ALAD FDPS 1422/4885SMN1; SMN2 2913/4885MEN1 3148/4885
US-20080194808-A1 CELLULOSE ESTERS AND THEIR PRODUCTION IN CARBOXYLATED IONIC LIQUIDS CEL, ACMSD, ACOT7 FDPS 1470/4885SMN1; SMN2 3897/4885MEN1 3042/4885
US-10174129-B2 Regioselectively substituted cellulose esters produced in a carboxylated ionic liquid process and products produced therefrom MGAM, CEL, MGAM2 FDPS 2522/4885SMN1; SMN2 2806/4885MEN1 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.